Evidence map›Paper›PMID 42570970›Full record

ReviewDrug delivery and translational research2026

Advances in stimuli-responsive hydrogels for liver disease therapy: mechanisms, applications, and translational perspectives.

Yilin Kuang, Yuhang Li, Chang Xu, Jinyan Chen, Huigang Li, Chenghao Cao, Peiru Zhang, Zhu Li, Rongsen Wang, Jinxin Xu and 4 more

Abstract readReview
PubMed Publisher
In one paragraph

Review in Drug delivery and translational research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors.

Yilin Kuang *School of Clinical Medicine, Hangzhou Medical College, Hangzhou, China.
Yuhang Li *Zhejiang University School of Medicine, Hangzhou, China.
Chang Xu *School of Clinical Medicine, Hangzhou Medical College, Hangzhou, China.
Jinyan Chen *Zhejiang University School of Medicine, Hangzhou, China.
Huigang LiZhejiang University School of Medicine, Hangzhou, China.
Chenghao CaoZhejiang University School of Medicine, Hangzhou, China.
Peiru ZhangThe Fourth School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Zhu LiSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China.
Rongsen WangSchool of Basic Medical Sciences and Forensic Medicine, Hangzhou Medical College, Hangzhou, China.
Jinxin XuThe Second School of Clinical Medicine, Zhejiang Chinese Medical University, Hangzhou, China.
Hantian YinSchool of Clinical Medicine, Hangzhou Medical College, Hangzhou, China.
Jianyong ZhuoHepatobiliary Center and Transplantation Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. zhuojianyong@zju.edu.cn.
Xiao XuHepatobiliary Center and Transplantation Center, The First Affiliated Hospital with Nanjing Medical University, Nanjing, China. njxu@njmu.edu.cn.
Di LuGeneral Surgery, Cancer Center, Department of Hepatobiliary & Pancreatic Surgery and Minimally Invasive Surgery, Zhejiang Provincial People's Hospital (Affiliated People's Hospital), Hangzhou Medical College, Hangzhou, China. zjuludi@zju.edu.cn.ORCID https://orcid.org/0000-0002-8724-3739

Funding

Key Research & Development Plan of Zhejiang Province 2024C03051National Innovation Training Program for College Students 202613023034
6 · The paper itself

Abstract

The liver is a pivotal organ for metabolic and immune homeostasis, playing an essential role in maintaining physiological balance. Globally, the increasing incidence and mortality of liver diseases constitute a critical public health issue. However, conventional therapies are often limited by their inability to precisely target the pathological microenvironment of the liver, frequently resulting in either insufficient efficacy or excessive tissue damage. With notable biocompatibility, a tunable porous architecture, and smart responsive capabilities, hydrogels hold considerable promise as drug carriers for treating liver diseases. This review evaluates the core design principles and therapeutic value of stimuli-responsive hydrogels in liver disease, compares hydrogel systems, details their responsive modes, and highlights recent progress in antitumor, antioxidant, anti-fibrotic, and immunomodulatory therapy. Ultimately, the present review examines the key challenges and future directions for translating stimuli-responsive hydrogels into more precise, safe, and personalized therapies for liver diseases.

Indexed as

Drug deliveryHepatocellular carcinomaHydrogelsLiver diseasesLiver fibrosisStimuli-responsive biomaterials

Identifiers

PMID42570970

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.